viewChina Biologic Products

China Biologic beats analyst expectations and swings to third quarter profit


China Biologic Products (Nasdaq: CBPO), a Chinese biopharmaceutical company specializing in plasma-based products, said today that it swung to a profit for the third quarter on aggressive pricing strategies.

For the third quarter, profits attributable to the company were $13.7 million, or 53 cents per diluted share, compared to a loss of $6.2 million, or 29 cents per diluted share, for the year-ago period.

Excluding non-cash expenses and derivative gains and losses, third quarter profits attributable to the company were $10.5 million, or 39 cents per diluted share, up from $7.1 million, or 33 cents per diluted share, in the third quarter of 2009.

Meanwhile, third quarter revenues increased 33% year-over-year to $36 million, driven mainly by product price increases.

The results trumped analyst estimates, which typically exclude special items, of 32 cents per diluted share on revenues of $33.5 million.

The firm's antibody products, which make up half of the company's third quarter revenue, had average price increases ranging from 6.2% to 55.8%.

At quarter end, the company had about $123 million in current assets, about $64 million of which was in cash.  Total liabilities stood at roughly $67 million.

China Biologic also reaffirmed its guidance for 2010 adjusted profits between $34 million and $36 million.  Revenues for fiscal 2010 are expected to come in between $142 million and $149 million.

Since the news, the company's shares have rallied 3.2% to trade at $11.13 as of 1:48 pm EST.

Quick facts: China Biologic Products

Price: 119.54 USD

Market: NASDAQ
Market Cap: $4.64 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 8 hours ago

2 min read